Lifmior (etanercept)
- Region
- 🇪🇺 EU
- Active substance
- etanercept
- Company
- Pfizer Europe MA EEIG
- Status
- Lapsed
- Therapeutic area
- Arthritis, Psoriatic; Spondylitis, Ankylosing; Psoriasis
- CHMP opinion
- Thu 15 Dec 2016
- EU approval
- Mon 13 Feb 2017
- Application
- EMEA/H/C/004167
- ATC
- L04AB01
- Official record
- www.ema.europa.eu
Indication
Rheumatoid arthritis; Juvenile idiopathic arthritis Psoriatic arthritis; Axial spondyloarthritis; Plaque psoriasis; Paediatric plaque psoriasis.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Erelzi Authorised · Sandoz GmbH
- 🇪🇺 Fubelv Authorised · Biosimilar Collaborations Ireland Limited
- 🇪🇺 Benepali Authorised · Samsung Bioepis NL B.V.
- 🇪🇺 Enbrel Authorised · Pfizer Europe MA EEIG
- 🇪🇺 Nepexto Authorised · Biosimilar Collaborations Ireland Limited
Follow Lifmior
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.